Cisplatin for Chemotherapy
Cisplatin, a platinum-based chemotherapy drug, holds a pivotal role in the treatment of pleural mesothelioma. It was formerly known as Platinol®-AQ, a chemotherapy drug that has gained FDA approval for the treatment of pleural mesothelioma. This small platinum-containing molecule effectively interferes with cell growth and division, inducing cell death and arresting tumor growth.
Mesothelioma Treatment
In a significant development, the U.S. Food and Drug Administration (FDA) granted approval for the combination of cisplatin and pemetrexed (Alimta®) to treat pleural mesothelioma in 2004. Notably, cisplatin received its initial FDA approval in 1978 for treating testicular and bladder cancer. Moreover, cisplatin is also approved for ovarian cancer treatment.
Cisplatin’s Collaborative Role
Cisplatin is often employed in combination with other mesothelioma drugs to enhance treatment effectiveness. The combination of cisplatin and pemetrexed stands as the sole FDA-approved chemotherapy regimen for mesothelioma. However, ongoing research explores the potential benefits of combining cisplatin with other drugs, such as bevacizumab, doxorubicin, and gemcitabine, to deliver more comprehensive mesothelioma treatment.
Innovative Treatment Approaches
Cisplatin’s versatility extends to its role in innovative mesothelioma treatment techniques. These include:
- Heated Intraperitoneal Chemotherapy (HIPEC): Cisplatin is a key component of HIPEC procedures, involving a heated chemotherapy wash administered to the abdominal cavity after surgery. HIPEC has shown promise in improving survival rates for peritoneal mesothelioma patients.
- Hyperthermic Intrathoracic Chemotherapy (HITHOC): Similar to HIPEC, HITHOC employs heated chemotherapy drugs, including cisplatin, within the chest cavity. This approach targets pleural mesothelioma tumors, potentially enhancing survival outcomes.
Cisplatin and Pemetrexed for Pleural Mesothelioma
The FDA-approved combination of cisplatin and pemetrexed has significantly improved treatment options for pleural mesothelioma patients. Resection, the surgical removal of tissue, is often not feasible for unresectable tumors, making this combination a valuable therapeutic option. Research indicates that cisplatin and pemetrexed combination therapy results in better patient responses compared to cisplatin alone.
Benefits of Cisplatin
Cisplatin, in conjunction with pemetrexed, offers several benefits for individuals with pleural mesothelioma. This treatment regimen may enhance survival rates, particularly for patients ineligible for surgery. It stands as the only FDA-approved chemotherapy treatment for pleural mesothelioma.
Additional Therapies
Research has explored the potential advantages of combining cisplatin with other treatment modalities such as immunotherapy and Tumor Treating Fields (TTFields). These investigations suggest promising outcomes, indicating the value of a multi-pronged approach to mesothelioma care.
Side Effects
While cisplatin is generally well-tolerated, it may lead to side effects such as nausea, vomiting, fatigue, and loss of appetite. Managing these side effects effectively is essential to improve the quality of life during treatment.
Eligibility for Cisplatin Treatment
Determining eligibility for cisplatin treatment involves considering various factors, including performance status, drug allergies, pre-existing medical conditions, and other medications the patient may be taking. Consulting with a medical professional is crucial to assess suitability for cisplatin as part of a personalized treatment plan.
Cisplatin Infusion Schedule
Pleural mesothelioma patients typically receive cisplatin plus pemetrexed treatment infusions every three weeks, with four to six treatments over three to six months. Preparatory steps, including vitamin supplements and steroid injections, are taken to minimize side effects.
Managing Treatment and Follow-Up Care
During treatment, patients are encouraged to avoid infection-prone areas, prioritize rest, stay hydrated, and maintain good hand hygiene. Regular follow-up appointments are essential for monitoring patient progress and addressing any side effects.
Cisplatin’s Impact on Mesothelioma Care
Cisplatin’s approval and utilization have marked significant progress in mesothelioma treatment. As ongoing research explores new avenues, cisplatin continues to play a vital role in enhancing survival rates and improving the quality of life for mesothelioma patients.